ArticleFrontiers in immunology2018
Protective Role of the MER Tyrosine Kinase
Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Efferocytosis and inflammation: a bibliometric and systematic analysis.Frontiers in medicine · 2025Pooled it
- Targeting receptor tyrosine kinases: from molecular mechanisms to clinical therapeutics.Signal transduction and targeted therapy · 2026Review
- Obesity-Associated Osteoarthritis: Mechanical-Metabolic Pathogenesis, Obesity Memory and Dual-Target Therapy.Current obesity reports · 2026Review
- Neutrophil Extracellular Trap Formation-Derived Peptidylarginine Deiminases in the Citrullination of Oral Bacteria to Promote Inflammation in Rheumatoid Arthritis.The Journal of rheumatology · 2026Article
- Identification of potential key efferocytosis-related genes in rheumatoid arthritis using machine learning.Clinical rheumatology · 2026Article
- m⁶A-associated GAS6 expression is associated with pathogenic activation of fibroblast-like synoviocytes in rheumatoid arthritis.Scientific reports · 2026Article
- Review
- Lnc-CHRM4-2:1 Inhibits M2 Polarization and Efferocytosis of Macrophages by Downregulating MerTK and SLC2A1 in Rheumatoid Arthritis.Journal of immunology research · 2026Article
- Targeted phagocytosis of TNF-α by CAR macrophages restores immune homeostasis in arthritis.Theranostics · 2026Article
- Impaired Macrophage Efferocytosis: Shared Mechanisms and Therapeutic Implications in Immune-Mediated Inflammatory Diseases.Journal of inflammation research · 2026Review
- Engineering Efferocytosis for Bone Regeneration.Macromolecular bioscience · 2025Review
- Arginase-1 and Mer Tyrosine Kinase Expression in Monocyte Populations in Patients with Axial Spondyloarthritis.Bulletin of experimental biology and medicine · 2025Article
- Targeting Frequent Efferocytosis in Tumor Microenvironment is a New Direction for Cancer Treatment.Small science · 2025Review
- IĸBζ as a Central Modulator of Inflammatory Arthritis Pathogenesis.Arthritis & rheumatology (Hoboken, N.J.) · 2025Article
- Metabolic Implications of Efferocytosis During Inflammation.Advances in experimental medicine and biology · 2025Review
- Efferocytosis and Bone Dynamics.Current osteoporosis reports · 2024Review
- Transcriptional analysis of efferocytosis in mouse skin wounds.bioRxiv : the preprint server for biology · 2024Article
- Efferocytosis: Current status and future prospects in the treatment of autoimmune diseases.Heliyon · 2024Review
- Programmed Death Ligand 1-Expressing Macrophages and Their Protective Role in the Joint During Arthritis.Arthritis & rheumatology (Hoboken, N.J.) · 2024Article
- Macrophage re-programming by JAK inhibitors relies on MAFB.Cellular and molecular life sciences : CMLS · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Rheumatoid arthritis (RA) is a chronic and progressive joint disease. It appears that anti-inflammatory feedback mechanisms that could restrain joint inflammation and restore homeostasis are insufficient to perform this control. In this study, we investigated the contribution of the MER tyrosine kinase-mediated anti-inflammatory response on arthritis and whether targeting MER could be a valid approach to treat RA. Methods: KRN serum transfer arthritis (KRN STA) was induced in either Results: Conclusion: MER plays a protective role during joint inflammation and activating MER by its ligand PROS1 ameliorates disease. Treatment of mice with MER receptor agonistic antibodies is deleterious due to its counterproductive effect of blocking efferocytosis in the arthritic joint.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.